Oral Vancomycin vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection (PREVAN)

  • End date
    Jul 20, 2024
  • participants needed
  • sponsor
    Julia Orígüen
Updated on 4 October 2022


A phase III randomized clinical trial in proportion 2:1 in favor of oral vancomycin (experimental treatment), multicentric, national, double-blinded, controlled with placebo. The main objective is to evaluate the effectiveness of treatment with oral vancomycin to reduce the incidence of Clostridioides difficile infection (CDI) in patients who suffered previous CDI and who need further hospitalization and treatment with systemic antibiotic therapy in the 90 days after the first CDI.


As secondary objectives the investigators intend to:

  • Evaluate the effectiveness of the treatment with oral vancomycin as part of the prophylaxis arsenal to prevent ICD in patients with previous ICD episodes stratified by the number of previous recurrences.
  • Compare the severity of recurrences in both study groups.
  • Compare the effectiveness of the treatment with oral vancomycin depending on the type of systemic antibiotic therapy prescribed.
  • Evaluate the tolerance and the safety of the treatment with oral vancomycin in terms of secondary effects and difficulty in therapeutic compliance.
  • Evaluate if the treatment with oral vancomycin has an effect in diminishing the severity of ICD recurrences.

Condition Clostridioides Difficile Infection
Treatment Placebo, Oral Vancomycin
Clinical Study IdentifierNCT05320068
SponsorJulia Orígüen
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Age equal or superior to 18 years
Previous history of Clostridioides difficile infection in the 90 days before the study enrolment
Need for hospitalization and need of antibiotic therapy
Signature of informed consent

Exclusion Criteria

Woman of childbearing age, pregnant woman, or breastfeeding woman
Patients allergic to vancomycin
Impossibility of fulfilling the study protocol
Critically ill condition or life expectancy less than 30 days
Patients with diagnosed inflammatory bowel disease or with any conditions that produce chronic diarrhea
Patients that meet diarrhea criteria or that present a Clostridioides Difficile infection at the time of patient's recruitment or during the 3 days prior
Antibiotic therapy with oral vancomycin at the time of patient's selection or during the 3 days prior, or with any drug that is effective against Clostrioides Difficile
Antibiotic prophylaxis with oral vancomycin or with any drug that is effective against Clostrioides difficile during the 90 days before the recruitment
Systemic antibiotic therapy for 72 hours or more before the recruitment
Enrolment in another clinical trial that evaluates other drugs' effectiveness
Estimated use of systemic antibiotic therapy for more than 4 weeks
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note